1Jones A R, Shusta E V. Blood brain barrier transport of therapeutics via receptor mediation [ J ]. Pharm Res,2007, 24 ( 9 ) : 1759.
2Pradridge W M. Molecular Trojan horses for bloodbrain barrier th'ug de- livery[J]. Curr Opin Phamlacol, 2006, 6(5 ) :494.
3Kreuter J, Swarbrcik J C. Encyclopedia of Pharmaceutical Tethnology [ M ]. Third Edition Volume Set. NewYork : Maecel, 1994 :1 65.
4Grayson M S, Freehet J M J. Convergent dendrons and dendrimers[ J]. Chem Rev,2001 ,101:3819.
5Bosman W A, Janssen M H, Meijer W. About dendrimers: structure, physical property and functions [ J ]. Chem Rev, 1999, 99 (7) : 1665.
6Huang R Q, Qu Y H, Ke W L, et al. Efficient gene delivery targeted to the brain using a transferrin - conjugated polyethyleneglycol - modified polyamidoamine dendrimer[ J ]. Faseb J,2007,21 : 1117.
7He H, Li Y, Jia X R, et al. PEGylated Poly(amidoarnine) dendrimer - based dual - targeting carrier for treating brain tumors[ J]. Biomateri- als,2011 ,32(2) :478.
8Li Y, He H, Jia X, et al. A dual -targeting nanocarrier based on poly (amidoamine) dendrimers conjugated with transirrin and tamoxifen for treating brain gliomas[J]. Biomaterials, 2012, 33:3899.
2[1]Devile C,Packer R,Walker D,et al.What's new in neuro-on-cology.Eur J Paediatr Neurol,2000,4:255-262.
3[2]Kyo S,Inoue M.Complex regulatory mechanisms of telomerase activity in normal and cancer cells:how can we apply them for cancer therapy? Oncogene,2002,21:688-697.
4[3]Le S,Zhu JJ,Anthony DC,et al.Telomerase activity in human gliomas.Neurosurgery,1998,42:1120-1125.
5[5]Kraemer K,Fuessel S,Schmidt U,et al.Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells.Clin Cancer Res,2003,9(10 Pt 1):3794-3800.
7[7]Zhang L,Yang N,Mohamed-Hadley A,et al.Vector-based RNAi,a novel tool for isoform-specific knock-down of VEGF and antiangiogenesis gene therapy of cancer.Biochem Biophys Res Commun,2003,303:1169-1178.
8[8]Sui G,Soohoo C,Affar el B,et al.A DNA vector-based RNAi technology to suppress gene expression in mammalian cells.Proc Natl Acad Sci USA,2002,99:5515-5520.
9[9]Brummelkamp TR,Bernards R,Agami R.A system for stable expression of short interfering RNAs in mammalian cells.Science,2002,296:550-553.
10[10]Kosciolek BA,Kalantidis K,Tabler M,et al.Inhibition of telomerase activity in human cancer cells by RNA interference.Mol Cancer Ther,2003,2:209-216.
3Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 [J]. Neuro Oncol, 2015, 17 Suppl 4: ivl-iv62, doi: 10,1093/neuonc/nov189.
4Ellis HP, Greenslade M, Powell B, et al. Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Dis- ease, and Models to Predict Disease Recurrence [J]. Front Oncol, 2015, 5: 251. doi: 10.3389/fonc,2015.00251.
5Lima FR, Kahn SA, Soletti RC, et al. Glioblastoma: therapeutic challenges, what lies ahead [J]. Biochim Biophys Acta, 2012, 1826(2): 338-349. doi: 10,1016/ j.bbcan,2012.05.004.
6Champ CE, Siglin J, Mishra MV, et al. Evaluating changes in radiation treatment volumes from post-operative to same- day planning MRI in High-grade gliomas [J]. Radiat Oncol, 2012, 7: 220. doi: 10,1186/1748-717X-7-220.
8Zhan C, Li B, Hu L, et al. Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine recep- tor ligand [J]. Angew Chem Int Ed Engl, 2011, 50(24): 5482-5485. doi: 10,1002/anie,201100875.
9Lu W, Wan J, She Z, et al. Brain delivery property and ac- celerated blood clearance of cationic albumin conjugated pegylated nanoparticle [J]. J Control Release, 2007, 118(1): 38-53.
10Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer [J]. Biochim Biophys Acta, 2011, 1816(2): 232-246. doi: 10,1016/ j.bbcan,2011.07.006.
